Effient (prasugrel) Disease Interactions
There are 3 disease interactions with Effient (prasugrel):
Prasugrel (Includes Effient) ↔ bleeding
Severe Potential Hazard, Moderate plausibility. Applies to: Bleeding
Prasugrel is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage, as this agent increases the risk of fatal bleeding.
Prasugrel (Includes Effient) ↔ CAD
Severe Potential Hazard, Moderate plausibility. Applies to: Ischemic Heart Disease
Prasugrel is contraindicated in patients with a history of prior transient ischemic attack (TIA) or stroke. Patients who experience a stroke or TIA while on prasugrel generally should have therapy discontinued. The risk of bleeding is increased in patients receiving prasugrel who undergo coronary artery bypass graft. If possible, prasugrel should be discontinued at least 7 days prior to the procedure.
Prasugrel (Includes Effient) ↔ renal/liver disease
Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease, Renal Dysfunction
No dosage adjustment is necessary for patients with renal impairment. No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. Caution should be exercised in patients with end-stage renal disease and those with severe hepatic disease as such patients are generally at higher risk of bleeding.
Effient (prasugrel) drug interactions
There are 249 drug interactions with Effient (prasugrel)
More about Effient (prasugrel)
- Effient Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Compare Alternatives
- Support Group
- Pricing & Coupons
- En Español
- 14 Reviews
- Generic Availability
- Drug class: platelet aggregation inhibitors
- FDA Alerts (1)
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.